68 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author이민형-
dc.date.accessioned2018-03-24T01:28:19Z-
dc.date.available2018-03-24T01:28:19Z-
dc.date.issued2013-10-
dc.identifier.citationJOURNAL OF CONTROLLED RELEASE, 2013, 171(1), P.1-10en_US
dc.identifier.issn0168-3659-
dc.identifier.urihttps://ac.els-cdn.com/S0168365913003805/1-s2.0-S0168365913003805-main.pdf?_tid=6db6873e-d722-4ea9-b129-5d55cdb67485&acdnat=1521115046_eb25d7ebdffd0b6ccef91a5ca78f35ca-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/51704-
dc.description.abstractGene therapy is suggested as a promising alternative strategy of hepatocellular carcinoma (HCC, also called hepatoma) therapy. To achieve a successful and safe gene therapy, tight regulation of gene expression is required to minimize side-effects in normal tissues. In this study, we developed a novel hypoxia and hepatoma dual specific gene expression vector. The constructed vectors were transfected into various cell lines using bio-reducible polymer, PAM-ABP. First, pAFPS-Luc or pAFPL-Luc vector was constructed with the alpha-fectoprotein (AFP) promoter and enhancer for hepatoma tissue specific gene expression. Then, pEpo-AFPL-Luc was constructed by insertion of the erythropoietin (Epo) enhancer for hypoxic cancer specific gene expression. In vitro transfection assay showed that pEpo-AFPL-Luc transfected hepatoma cell increased gene expression under hypoxic condition. To confirm the therapeutic effect of dual specific vector, herpes simplex virus thymidine kinase (HSV-TK) gene was introduced for cancer cell killing. The pEpo-AFPL-TK was transfected into hepatoma cell lines in the presence of ganciclovir (GCV) pro-drug. Caspase-3/7, MTT and TUNEL assays elucidated that pEpo-AFPL-TK transfected cells showed significant increasing of death rate in hypoxic hepatoma cells compared to controls. Therefore, the hypoxia/hepatoma dual specific gene expression vector with the Epo enhancer and AFP promoter may be useful for hepatoma specific gene therapy. (C) 2013 Elsevier B.V. All rights reserved.en_US
dc.description.sponsorshipThis work was supported by the NIH Grant CA107070 (S.W. Kim) and grants from the National Research Foundation in Korea funded by the Ministry of Education, Science and Technology 2012K001394 (M. Lee) and Basic Science Research Program 2012R1A6A3A03040715 (H.A. Kim).en_US
dc.language.isoenen_US
dc.publisherELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSen_US
dc.subjectHepatomaen_US
dc.subjectGene regulationen_US
dc.subjectSuicide gene therapyen_US
dc.subjectBio-reducible polymeren_US
dc.subjectCancer hypoxiaen_US
dc.subjectALPHA-FETOPROTEIN PROMOTERen_US
dc.subjectSELECTIVE CANCER-THERAPYen_US
dc.subjectVIRUS THYMIDINE KINASEen_US
dc.subjectRECURRENT GLIOBLASTOMAen_US
dc.subjectPHASE-Ien_US
dc.subjectHYPOXIAen_US
dc.subjectVECTORen_US
dc.subjectMYOCARDIUMen_US
dc.subjectHEPATOMAen_US
dc.subjectTARGETen_US
dc.titleHypoxia/hepatoma dual specific suicide gene expression plasmid delivery using bio-reducible polymer for hepatocellular carcinoma therapyen_US
dc.title.alternativehepatoma dual specific suicide gene expression plasmid delivery using bio-reducible polymer for hepatocellular carcinoma therapyen_US
dc.typeArticleen_US
dc.relation.no1-
dc.relation.volume171-
dc.identifier.doi10.1016/j.jconrel.2013.06.033-
dc.relation.page1-10-
dc.relation.journalJOURNAL OF CONTROLLED RELEASE-
dc.contributor.googleauthorKim, Hyun Ah-
dc.contributor.googleauthorNam, Kihoon-
dc.contributor.googleauthorLee, Minhyung-
dc.contributor.googleauthorKim, Sung Wan-
dc.relation.code2013010611-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF ENGINEERING[S]-
dc.sector.departmentDEPARTMENT OF BIOENGINEERING-
dc.identifier.pidminhyung-
Appears in Collections:
COLLEGE OF ENGINEERING[S](공과대학) > BIOENGINEERING(생명공학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE